Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJ. Gregory DolanJTJulie‐An TalanoABAlice Bertaina

Discussion

Loading...

Member takes

Overview

Planned analysis shows NGS-MRD positivity pre-transplant predicts poorer outcomes in B-ALL, suggesting better monitoring practices are needed.

Key Points

  • Pre-HCT positive minimal residual disease by NGS linked to significantly poorer overall survival outcomes.
  • NGS demonstrates higher sensitivity in detecting residual disease compared to traditional methods, predicting higher relapse rates.
  • Cox proportional hazards models indicated strong predictive power for outcomes related to NGS and minimal residual disease.
  • The findings underline the importance of effective monitoring strategies in managing patients with B-ALL undergoing transplantation.

Cite This Study

Dolan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e18dhttps://doi.org/10.1182/blood-2025-511
View Full Paper
Ask AI
Bookmark
Share